CIK 0000730272 · Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 042729386
- Phone
- 7814499560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,953,260
- in 5 filings, $6.0M under 10b5-1 plans
Net −$5,953,260. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-02 | KURIYEL RALF Senior VP, R&D | Option exercise | +175 | $86.10 | $15K | 12,463 |
| 2024-08-02 | KURIYEL RALF Senior VP, R&D | Sale | −175 | $158.85 | $28K | 12,288 |
| 2024-08-02 | KURIYEL RALF Senior VP, R&D | Option exercise · Stock Option (Right to Buy) | +175 | 0 | ||
| 2024-08-01 | KURIYEL RALF Senior VP, R&D | Sale | −4,465 | $165.67 | $740K | 19,261 |
| 2024-08-01 | MUIR GLENN P Director | Option exercise | +5,000 | $36.29 | $181K | 13,283 |
| 2024-08-01 | MUIR GLENN P Director | Option exercise · Stock Option (Right to Buy) | +5,000 | 0 | ||
| 2024-06-14 | Madaus Martin D Director | Purchase | +915 | $124.54 | $114K | 3,913 |
| 2024-06-14 | Madaus Martin D Director | Purchase | +700 | $125.46 | $88K | 4,613 |
| 2024-06-14 | BARTHELEMY NICOLAS Director | Purchase | +1,200 | $125.45 | $151K | 4,668 |
| 2024-06-14 | Hunt Anthony Chief Executive Officer | Purchase | +2,000 | $124.08 | $248K | 165,177 |
| 2024-06-14 | DAWES KAREN A Director | Option exercise | +2,953 | $67.71 | $200K | 88,170 |
| 2024-06-14 | DAWES KAREN A Director | Option exercise · Stock Option (Right to Buy) | +2,953 | 0 | ||
| 2024-05-21 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −4,274 | $166.36 | $711K | 178,975 |
| 2024-05-21 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −4,008 | $167.05 | $670K | 174,967 |
| 2024-05-21 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −3,933 | $168.33 | $662K | 171,034 |
| 2024-05-21 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −2,963 | $169.27 | $502K | 168,071 |
| 2024-05-21 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −3,925 | $170.04 | $667K | 164,146 |
| 2024-05-21 | Hunt Anthony Chief Executive Officer | Sale 10b5-1 | −969 | $171.03 | $166K | 163,177 |
| 2024-05-16 | Madaus Martin D Director | Grant or award | +701 | 2,998 | ||
| 2024-05-16 | Madaus Martin D Director | Grant or award · Stock Option (Right to Buy) | +1,376 | 1,376 |
Page 10 of 11 · 215 trades